Colorectal Disorders

Xeljanz Gets FDA Committee Nod for Ulcerative Colitis Indication

By March 09, 2018

The GIDAC recommendations are provided to the FDA but they are not binding. The FDA has set a target PDUFA action date of June 2018.

Limited Data on Combination Biologic Therapy for IBD, Says Study

By February 28, 2018

The authors point out how, unlike other autoinflammatory conditions, "IBD has the benefit of effective and safe gut specific anti-integrin therapies which can provide a platform off of which combinations can be employed."

Modifiable Risk Factors ID'd in Recurring Acute Diverticulitis

February 23, 2018

"Knowledge of the rate and risk factors for recurrent acute diverticulitis is required to aid discussion and decision making with patients regarding the need and timing of elective surgery," the authors write.

Recurrent Salmonella enterica Typhimurium infection disables host protection against intestinal inflammation

February 04, 2018

Repeated gastrointestinal infections in mice, in this case Salmonella enterica Typhimurium (ST), caused intestinal tissue inflammation which escalated with repeated infections.

Firvanq Approved for <i>C. difficile</i>-Associated Diarrhea, <i>S. aureus</i> Colitis

By January 29, 2018

Firvanq oral solution will replace CutisPharma's FIRST-Vancomycin Unit-of-Use Compounding Kit, which was used by pharmacists to compound vancomycin oral liquid.

Trulance Gains New Indication for IBS With Constipation

By January 25, 2018

Apart from a single amino acid substitution, Trulance is structurally identical to human uroguanylin and is thought to replicate the pH-sensitive activity of uroguanylin.

Olmesartan Use Linked to Higher Rate of Enteropathy Compared to Other ARBs

By January 23, 2018

The authors note that while the evidence points to a higher rate of enteropathy outcomes in patients treated with olmesartan, the absolute rate was found to be low.

Reduced Stoma-Related Care Costs With Ceramide-Infused Ostomy Skin Barrier

January 16, 2018

The researchers found that over a 12-week period there was a significant reduction in stoma-related cost of care with use of the ceramide-infused barrier, resulting in a 14% relative decrease in cost.

Treating a Common Extraintestinal Manifestation of Inflammatory Bowel Disease

January 05, 2018

Mr. C, a 30-year-old male with Crohn's disease, presented to his clinician with symptoms of fatigue, lethargy, headaches, pallor, hair loss, irritability, and weakness.

Treatment Response Predictors ID'd for Infliximab Salvage in Severe UC

January 03, 2018

Those treated with accelerated (AI) versus standard infliximab induction strategies had a numerically higher colectomy rate; however, AI treatment was correlated with more severe biochemical disease.

Biosimilar Ixifi Gets FDA Approval for All Remicade Indications

By December 14, 2017

Ixifi is a chimeric human-murine monoclonal antibody (mAb) against tumor necrosis factor.

Sanofi Discontinues <i>C. Difficile</i> Tx Development

By December 08, 2017

Data that has been collected from the trial so far will be analyzed and shared with the scientific community in due time.

Safety and Efficacy of Switching Infliximab to Biosimilar in IBD

By December 06, 2017

Results showed that disease activity scores before and after switching were not statistically significantly different (Crohn's disease activity index: P=.5657 and Truelove-Witts disease activity index: P=.7609).

Polyethylene Glycol vs. Pulsed Irrigation Evacuation for Colon Prep

December 06, 2017

The researchers found that PIE and sodium phosphate were superior to PEG, with both receiving a score of 4 on a 5-point scale (blind assessment), versus a 3 for PEG (P<0.01).

Pediatric Ulcerative Colitis Tx Granted Orphan Drug Status

By December 04, 2017

The designation is based on a review of Phase 1b clinical data which showed potential for SER-287 as a novel treatment modality for patients with UC

IV Iron Sucrose Evaluated for Iron Deficiency Anemia in Pediatric IBD

By December 01, 2017

Results of the review also found that 18 adverse events occurred in a total of 13 patients (18.1% of patients; 6.6% of infusions).

Fecal Microbial Transplant via Oral Capsule Versus Colonoscopy

November 29, 2017

The researchers found that prevention of recurrent CDI after a single treatment was achieved by 96.2% of participants in the capsule and colonoscopy groups in the per-protocol analysis (difference, 0%), meeting the criterion for noninferiority.

Fish Consumption May Trigger Food Protein-Induced Enterocolitis

October 31, 2017

The number of reactions before diagnosis was four on average. The main symptoms at the debut were vomiting and vomiting with diarrhea (97.5 and 30%, respectively), which occurred in a mean time of 126.3 minutes after ingestion of the culprit fish.

Orphan Drug Status Granted to Tx for Rare Bowel Disorder

By October 25, 2017

A Phase 2 trial demonstrated how glepaglutide treatment was associated with reduced fecal wet weight output as well as indicated increases in energy, fluid and electrolyte absorption.

Does Breastfeeding Protect Against Future Inflammatory Bowel Conditions?

By October 25, 2017

The researchers found that ever being breastfed was associated with a lower risk of CD and UC (OR 0.71, 95% CI 0.59-0.85 and OR 0.78, 95% CI 0.67-0.91 respectively).

Treatment for Fistulizing Crohn's Disease Gets Orphan Drug Status

By October 24, 2017

Cx601 is a first-in-class allogeneic cell therapy intended for patients who have had an inadequate response to at least one conventional or biologic therapy.

Treating Iron Deficiency Anemia in Patients With Inflammatory Bowl Disorder

By October 19, 2017

Despite its frequency, iron deficiency anemia in patients with IBD it is often overlooked in clinical settings.

Mesalamine Formulation Switch Linked to Acute Renal Failure in UC Patient

By October 17, 2017

The 35-year-old male from Hawaii maintained clinical remission with Lialda, a once-daily formulation of mesalamine, and infliximab.

Same-Day vs. Split Dose Bowel Prep for Colonoscopy Compared

By October 16, 2017

Results showed that adenoma detection rate (ADR) did not differ between groups. Additionally willingness to repeat and tolerability did not differ.

New Therapeutic Drug Monitoring Test for Ustekinumab Announced

By October 16, 2017

By measuring drug and antibody concentrations physicians can adapt treatment strategies and guide patients toward more personalized medicine.

Noninvasive Test Monitors Healing Status in Crohn's Disease Patients

By October 16, 2017

The PROMETHEUS Monitr Crohn's Disease test can be used as an adjunct to endoscopy or by itself between endoscopies.

Impact of Early Azathioprine Use on Crohn's Disease Progression Evaluated

October 02, 2017

Prior bowel resection, smoking, and low hemoglobin tied to Crohn's-related surgery

Hair Regrowth in Alopecia Patients After Fecal Transplant for Recurrent CDI

By September 22, 2017

These 2 cases suggests that fecal transplants can have a profound immunological response not only limited to intestinal effects, say the authros.

Does Prenatal Biologic Therapy for IBD Affect Infant Vaccine Response?

By September 18, 2017

In addition, the researchers assayed umbilical cord blood samples from 33 infants to assess the concentration of biologic agents.

Higher Incidence of GI Symptoms in Female IBS Patients on Clopidogrel

By September 11, 2017

The results showed a higher proportion of patients with GI symptoms on clopidogrel (68%) compared to controls (60%, P=0.0011) that were Females (70% vs. 60%, P=0.0003) not Males (61 vs. 60%; P=0.8312).